CellaVision
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar! Sales recovery with all-time high in Americas
Organic sales growth:
Q2, 2026: 5.6% (7.6)
EBITDA margin:*
Q2, 2026: 27% (31)
April 1 – June 30, 2026
Net sales increased by 4.5% (1.9) to SEK 200 m (191).
Sales increased organically by 5.6% (7.6), currency effect -1.1% (-5.8).
EBITDA amounted to SEK 55 m (60).*
EBITDA margin amounted to 27% (31).*
Profit before tax amounted to SEK 41 m (48).
Earnings per share before and after dilution amounted to SEK 1.37 (1.58).
Cash flow from operating activities amounted to SEK 29 m (58).
Significant events during the period
Steve Ferguson has been appointed Chief Executive Officer (CEO) as of June 5, 2026.
At the Annual General Meeting April 28, 2026, Zlatko Rihter was elected as the new Chairman
of the Board of Directors and Louise Armstrong-Denby resigned as Board member.
* EBITDA for the second quarter 2026 was charged with expenses of SEK 9 m associated with the initial phase of the CEO transition. Adjusted for this, EBITDA and the EBITDA margin increased compared with the same quarter last year.
| Datum | 2026-07-17, kl 07:20 |
| Källa | MFN |